DK3959235T3 - RITUXIMAB-RESISTANT CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF - Google Patents

RITUXIMAB-RESISTANT CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF Download PDF

Info

Publication number: DK3959235T3
Authority: DK; Denmark
Prior art keywords: rituximab; chimeric antigen; antigen receptors; resistant chimeric; resistant
Prior art date: 2019-04-26

Application number

DK20728258.3T

Other languages

Danish (da)

Other versions

DK3959235T5 (en

Inventor

Thomas Charles Pertel

Barbra Johnson Sasu

Mark W Leonard

Original Assignee

Allogene Therapeutics Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2019-04-26

Filing date

2020-04-24

Publication date

2023-10-16

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=70847489&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3959235(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2020-04-24 Application filed by Allogene Therapeutics Inc filed Critical Allogene Therapeutics Inc

2023-10-16 Publication of DK3959235T3 publication Critical patent/DK3959235T3/en

2024-08-05 Application granted granted Critical

2024-08-05 Publication of DK3959235T5 publication Critical patent/DK3959235T5/en

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/31—Chimeric antigen receptors [CAR]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4202—Receptors, cell surface antigens or cell surface determinants
- A61K40/421—Immunoglobulin superfamily
- A61K40/4211—CD19 or B4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70517—CD8
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15041—Use of virus, viral particle or viral elements as a vector
- C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Immunology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Genetics & Genomics (AREA)
Zoology (AREA)
Epidemiology (AREA)
Biochemistry (AREA)
Cell Biology (AREA)
Biomedical Technology (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Biotechnology (AREA)
Biophysics (AREA)
Wood Science & Technology (AREA)
Toxicology (AREA)
Gastroenterology & Hepatology (AREA)
Hematology (AREA)
General Engineering & Computer Science (AREA)
Microbiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Virology (AREA)
Oncology (AREA)
Developmental Biology & Embryology (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

DK20728258.3T 2019-04-26 2020-04-24 RITUXIMAB-RESISTANT CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF DK3959235T5 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201962839455P	2019-04-26	2019-04-26
US202063005041P	2020-04-03	2020-04-03
PCT/US2020/029775 WO2020219848A1 (en)	2019-04-26	2020-04-24	Rituximab-resistant chimeric antigen receptors and uses thereof

Publications (2)

Publication Number	Publication Date
DK3959235T3 true DK3959235T3 (en)	2023-10-16
DK3959235T5 DK3959235T5 (en)	2024-08-05

Family

ID=70847489

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK20728258.3T DK3959235T5 (en)	2019-04-26	2020-04-24	RITUXIMAB-RESISTANT CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF

Country Status (21)

Country	Link
US (2)	US11896617B2 (en)
EP (2)	EP3959235B1 (en)
JP (2)	JP7664180B2 (en)
KR (1)	KR20220004076A (en)
CN (1)	CN113728001B (en)
AU (1)	AU2020263495B2 (en)
BR (1)	BR112021021178A2 (en)
CA (1)	CA3134308A1 (en)
CO (1)	CO2021014121A2 (en)
DK (1)	DK3959235T5 (en)
ES (1)	ES2961314T3 (en)
FI (1)	FI3959235T3 (en)
IL (1)	IL287487A (en)
MX (1)	MX2021012820A (en)
MY (1)	MY204280A (en)
PE (1)	PE20212369A1 (en)
PH (1)	PH12021552415A1 (en)
SA (1)	SA521430654B1 (en)
SG (1)	SG11202111031RA (en)
TW (1)	TWI865517B (en)
WO (1)	WO2020219848A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP7451410B2 (en) *	2017-10-31	2024-03-18	アロジーンセラピューティクス，インコーポレイテッド	Methods and compositions for allogeneic chimeric antigen receptor T cell administration
WO2022076685A1 (en) *	2020-10-09	2022-04-14	Seattle Children's Hospital (dba Seattle Children's Research Institute)	Methods and compositions comprising pd1 chimeric polypeptides
US20240316199A1 (en)	2020-12-30	2024-09-26	Alaunos Therapeutics, Inc.	Recombinant Vectors Comprising Polycistronic Expression Cassettes and Methods of Use Thereof
CN119700678A (en) *	2024-12-19	2025-03-28	武汉大学	Synthesis of steuximab nanospheres and method for coupling CAR-T cells by using steuximab nanospheres

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4975278A (en)	1988-02-26	1990-12-04	Bristol-Myers Company	Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
US6319494B1 (en)	1990-12-14	2001-11-20	Cell Genesys, Inc.	Chimeric chains for receptor-associated signal transduction pathways
IL104570A0 (en)	1992-03-18	1993-05-13	Yeda Res & Dev	Chimeric genes and cells transformed therewith
US5830462A (en)	1993-02-12	1998-11-03	President & Fellows Of Harvard College	Regulated transcription of targeted genes and other biological events
US5869337A (en)	1993-02-12	1999-02-09	President And Fellows Of Harvard College	Regulated transcription of targeted genes and other biological events
US5834266A (en)	1993-02-12	1998-11-10	President & Fellows Of Harvard College	Regulated apoptosis
US20030036654A1 (en)	1994-08-18	2003-02-20	Holt Dennis A.	Synthetic multimerizing agents
US5827642A (en)	1994-08-31	1998-10-27	Fred Hutchinson Cancer Research Center	Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
HK1047770A1 (en)	2000-02-24	2003-03-07	Xcyte Therapies, Inc.	Simultaneous stimulation and concentration of cells
US6797514B2 (en)	2000-02-24	2004-09-28	Xcyte Therapies, Inc.	Simultaneous stimulation and concentration of cells
US6867041B2 (en)	2000-02-24	2005-03-15	Xcyte Therapies, Inc.	Simultaneous stimulation and concentration of cells
CA2462628C (en)	2001-10-02	2019-08-20	Institut Clayton De La Recherche	Restricted expression lentiviral vectors
US20100196336A1 (en)	2006-05-23	2010-08-05	Dongsu Park	Modified dendritic cells having enhanced survival and immunogenicity and related compositions and methods
WO2011146862A1 (en)	2010-05-21	2011-11-24	Bellicum Pharmaceuticals, Inc.	Methods for inducing selective apoptosis
PH12013501201A1 (en)	2010-12-09	2013-07-29	Univ Pennsylvania	Use of chimeric antigen receptor-modified t cells to treat cancer
WO2012103279A2 (en)	2011-01-26	2012-08-02	Ariad Pharmaceuticals, Incorporated	Methods and compositions for the synthesis of multimerizing agents
NZ743310A (en)	2011-03-23	2022-11-25	Fred Hutchinson Cancer Center	Method and compositions for cellular immunotherapy
GB201206559D0 (en)	2012-04-13	2012-05-30	Ucl Business Plc	Polypeptide
HUE064187T2 (en) *	2012-05-25	2024-02-28	Cellectis	Procedure for modification of allogeneic and immunosuppressive-resistant T cells suitable for immunotherapy
KR102064230B1 (en)	2013-02-15	2020-01-13	더 리젠츠 오브 더 유니버시티 오브 캘리포니아	Chimeric Antigen Receptor and Methods of Use Thereof
KR20150131218A (en)	2013-03-14	2015-11-24	벨리쿰 파마슈티컬스, 인크.	Methods for controlling t cell proliferation
BR112015028387B1 (en)	2013-05-13	2023-04-11	Cellectis	CD19-SPECIFIC CHIMERIC ANTIGEN RECEPTOR, POLYNUCLEOTIDE, EXPRESSION VECTOR, IN VITRO METHOD FOR HANDLING AND USE OF AN IMMUNE CELL
CA2956667A1 (en)	2013-07-29	2015-02-05	Bluebird Bio, Inc.	Multipartite signaling proteins and uses thereof
JP6793902B2 (en)	2013-12-20	2020-12-02	ノバルティスアーゲー	Adjustable chimeric antigen receptor
EP4215603A1 (en)	2014-02-04	2023-07-26	Kite Pharma, Inc.	Methods for producing autologous t cells useful to treat b cell malignancies and other cancers and compositions thereof
CN106132423B (en)	2014-02-14	2020-07-31	贝里坤制药股份有限公司	Methods of activating T cells with inducible chimeric polypeptides
GB201403972D0 (en) *	2014-03-06	2014-04-23	Ucl Business Plc	Chimeric antigen receptor
ES2791248T3 (en) *	2014-08-19	2020-11-03	Novartis Ag	Anti-CD123 chimeric antigen receptor (CAR) for use in cancer treatment
JP6868554B2 (en) *	2014-09-02	2021-05-12	ベリカムファーマシューティカルズ，インコーポレイテッド	Co-stimulation of chimeric antigen receptor with MyD88 and CD40 polypeptides
KR102329836B1 (en)	2015-01-26	2021-11-19	셀렉티스	Anti-CLL1 specific single-chain chimeric antigen receptors (scCARS) for cancer immunotherapy
GB201518792D0 (en) *	2015-10-23	2015-12-09	Univ Manchester	Production of proteins
WO2017103613A1 (en) *	2015-12-18	2017-06-22	Ucl Business Plc	Treatment
US20190241910A1 (en) *	2016-03-11	2019-08-08	Bluebird Bio, Inc.	Genome edited immune effector cells
WO2017180587A2 (en) *	2016-04-11	2017-10-19	Obsidian Therapeutics, Inc.	Regulated biocircuit systems
GB201609597D0 (en)	2016-06-01	2016-07-13	Univ Sheffield	Therapy
SG10202001869VA (en) *	2017-03-03	2020-04-29	Obsidian Therapeutics Inc	Cd19 compositions and methods for immunotherapy
PT3592379T (en) *	2017-03-31	2024-05-31	Cellectis Sa	Universal anti-cd22 chimeric antigen receptor engineered immune cells
US20210189361A1 (en)	2018-04-23	2021-06-24	Duke University	Downregulation of snca expression by targeted editing of dna-methylation
SG11202101996QA (en) *	2018-08-28	2021-03-30	Immunotech Biopharm Co Ltd	Improved therapeutic t cell

2020
- 2020-04-24 FI FIEP20728258.3T patent/FI3959235T3/en active
- 2020-04-24 US US16/857,573 patent/US11896617B2/en active Active
- 2020-04-24 BR BR112021021178A patent/BR112021021178A2/en unknown
- 2020-04-24 DK DK20728258.3T patent/DK3959235T5/en active
- 2020-04-24 PE PE2021001764A patent/PE20212369A1/en unknown
- 2020-04-24 ES ES20728258T patent/ES2961314T3/en active Active
- 2020-04-24 EP EP20728258.3A patent/EP3959235B1/en active Active
- 2020-04-24 TW TW109113823A patent/TWI865517B/en active
- 2020-04-24 KR KR1020217036085A patent/KR20220004076A/en active Pending
- 2020-04-24 CA CA3134308A patent/CA3134308A1/en active Pending
- 2020-04-24 CN CN202080031593.1A patent/CN113728001B/en active Active
- 2020-04-24 PH PH1/2021/552415A patent/PH12021552415A1/en unknown
- 2020-04-24 EP EP23186544.5A patent/EP4295851A3/en active Pending
- 2020-04-24 WO PCT/US2020/029775 patent/WO2020219848A1/en not_active Ceased
- 2020-04-24 JP JP2021563352A patent/JP7664180B2/en active Active
- 2020-04-24 MY MYPI2021005771A patent/MY204280A/en unknown
- 2020-04-24 AU AU2020263495A patent/AU2020263495B2/en active Active
- 2020-04-24 MX MX2021012820A patent/MX2021012820A/en unknown
- 2020-04-24 SG SG11202111031RA patent/SG11202111031RA/en unknown
2021
- 2021-10-21 SA SA521430654A patent/SA521430654B1/en unknown
- 2021-10-21 IL IL287487A patent/IL287487A/en unknown
- 2021-10-22 CO CONC2021/0014121A patent/CO2021014121A2/en unknown
2023
- 2023-12-26 US US18/395,996 patent/US12447178B2/en active Active
2025
- 2025-04-07 JP JP2025063227A patent/JP2025109712A/en active Pending

Also Published As

Publication number	Publication date
IL287487A (en)	2021-12-01
EP3959235B1 (en)	2023-07-26
ES2961314T3 (en)	2024-03-11
JP7664180B2 (en)	2025-04-17
EP4295851A2 (en)	2023-12-27
JP2025109712A (en)	2025-07-25
PH12021552415A1 (en)	2022-07-11
US12447178B2 (en)	2025-10-21
EP3959235A1 (en)	2022-03-02
AU2020263495A1 (en)	2021-10-28
US11896617B2 (en)	2024-02-13
PE20212369A1 (en)	2021-12-21
MX2021012820A (en)	2021-11-25
TW202106704A (en)	2021-02-16
KR20220004076A (en)	2022-01-11
BR112021021178A2 (en)	2022-03-15
MY204280A (en)	2024-08-21
EP4295851A3 (en)	2024-02-14
AU2020263495B2 (en)	2025-09-25
CA3134308A1 (en)	2020-10-29
CN113728001B (en)	2025-09-09
SG11202111031RA (en)	2021-11-29
WO2020219848A1 (en)	2020-10-29
FI3959235T3 (en)	2023-09-27
SA521430654B1 (en)	2024-08-11
US20200384026A1 (en)	2020-12-10
TWI865517B (en)	2024-12-11
CO2021014121A2 (en)	2021-10-29
DK3959235T5 (en)	2024-08-05
US20240277763A1 (en)	2024-08-22
CN113728001A (en)	2021-11-30
JP2022532996A (en)	2022-07-21

Publication	Publication Date	Title
IL280029A (en)	2021-03-01	ROR-1 specific chimeric antigen receptors and their uses
DK3802608T3 (en)	2025-06-10	ANTI-CD3 ANTIBODIES AND USES THEREOF
IL284216A (en)	2021-08-31	Anti-transferrin receptor antibodies and uses thereof
IL284744A (en)	2021-08-31	GPRC5D chimeric antigen receptors and cells expressing them
DK4324851T3 (en)	2025-10-06	Chimeric antigen receptors with BCMA specificity and uses thereof
EP3999550A4 (en)	2023-09-06	CHIMERIC ANTI-DLL3 ANTIGEN RECEPTORS AND USES THEREOF
IL285943A (en)	2021-10-31	Chimeric antigen receptors and dll3 binding mediators
IL280915A (en)	2021-04-29	Single chain chimeric polypeptides and uses thereof
EP3797122A4 (en)	2022-04-20	ANTI-ROR ANTIBODY CONSTRUCTS
EP3658163A4 (en)	2021-08-04	NOVEL CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF
KR102763158B9 (en)	2025-06-19	Optimized anti-TL1A antibodies
PL3436079T3 (en)	2021-12-20	CHIMERIC ANTIGEN AND T-CELL RECEPTORS AND THEIR APPLICATION
IL289354A (en)	2022-02-01	Anti-154cd antibodies and their uses
IL281428A (en)	2021-04-29	chimeric antigen receptor
DK3383916T3 (en)	2022-03-28	Anti-CD73 antibodies and uses thereof
EP3898691A4 (en)	2022-09-14	TREM2 ANTIBODIES AND USES THEREOF
IL286984A (en)	2021-12-01	Human anti-dll3 chimeric antigen receptors and their use
DK3286223T5 (en)	2024-10-07	KAPPA MYELOMA ANTIGEN CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF
PL3618928T3 (en)	2023-05-02	ANTISORTILIN ANTIBODIES AND THEIR USE
IL280033A (en)	2021-03-01	Uses of anti-BCMA chimeric antigen receptors
IL285909A (en)	2021-10-31	Chimeric antigen receptors against bcma
IL276836A (en)	2020-10-29	CD83-binding chimeric antigen receptors
EP4032907A4 (en)	2023-07-05	BCMA-TARGETED ANTIBODY AND CHIMERIC ANTIGEN RECEPTOR
EP3806903A4 (en)	2022-03-02	CHEMERA ANTI-CD79A ANTIGEN RECEPTORS
IL281297A (en)	2021-04-29	Anti-NPR1 antibodies and uses thereof